Edouard Fu

Hi, I am Edouard Fu, PhD FERA. I work as Assistant Professor at LUMC and as editor at NDT, and I am training to become MD.

My background is in epidemiology, with a focus on causal inference and cardiorenal therapies. Recently, I completed a postdoc at Harvard and was editorial fellow at the leading kidney journal JASN (2021-2023). My main research focuses on determining the effectiveness and safety of medications and treatments in patients with cardiometabolic or kidney diseases, by applying state-of-the art causal inference methods to routinely collected “big” healthcare data. I aspire to improve clinical care, and so far my work has informed eight international clinical practice guidelines and position statements.

Clinical impact
Key publications
Team
Talks

Our impact on clinical guidelines

Our research has informed eight (inter)national clinical practice guidelines and position statements:

Guideline / position statement	Recommendation	Informed by
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD (2024)	Practice Point 3.6.7: Continue ACEi or ARB in people with CKD even when the eGFR falls below 30ml/min per 1.73m2.	Fu et al. J Am Soc Nephrol 2021
European Federation of Clinical Chemistry and Laboratory Medicine Task Group on Chronic Kidney Disease (2024)	Recommendations for European laboratories based on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.	Fu et al. JASN 2023; Fu et al. NDT 2024
Ethical considerations on the use of big data and artificial intelligence in kidney research from the ERA ethics committee (2024)	How high-quality observational studies can complement randomized trial evidence by benchmarking results against trial findings and then extending them.	Fu et al. BMJ 2021
KDIGO guideline on CKD Evaluation and Management (2023)	Optimal timing of dialysis (practice point 5.4.3).	Fu et al. BMJ 2021
	Use eGFRcr-cys when eGFRcr is less accurate (practice point 1.2.2.1).	Fu et al. J Am Soc Nephrol 2023
	Continue ACE/ARB in people with advanced CKD (practice point 3.5.7).	Fu et al. J Am Soc Nephrol 2021
	Discontinue ACEi/ARB/MRA after AKI or hyperkalemia (practice point 4.3.3).	Janse, Fu et al. CKJ 2022; Xu, Fu et al. Am Heart J 2022; Trevisan, Fu et al. Eur J Heart Fail 2021; Bidulka, Fu et al. BMC Med 2020
	Overview of evaluation, diagnosis and staging of CKD (chapter 1 of guideline).	CKD Prognosis Consortium. JAMA 2023
European Renal Association position statement (2023)	Whether CKD-EPI 2021 equation should be implemented in Europe. The statement was adopted by the Dutch Federation of Nephrology.	Fu et al. NDT 2023
European Federation of Clinical Chemistry and Laboratory Medicine position statement (2023)	Whether CKD-EPI 2021 equation should be implemented in Europe. The statement was adopted by the Dutch Federation of Nephrology.	Fu et al. NDT 2023
KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD (2022)	Stopping vs. continuing ACEi/ARB	Fu et al. J Am Soc Nephrol 2021
NICE real-world evidence guideline (2022)	How observational real-world evidence studies should be performed (our paper was used as positive use-case)	Fu et al. BMJ 2021

Guideline / position statement

Recommendation

Informed by

KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD (2024)

Practice Point 3.6.7: Continue ACEi or ARB in people with CKD even when the eGFR falls below 30ml/min per 1.73m2.

Fu et al. J Am Soc Nephrol 2021

European Federation of Clinical Chemistry and Laboratory Medicine Task Group on Chronic Kidney Disease (2024)

Recommendations for European laboratories based on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.

Fu et al. JASN 2023; Fu et al. NDT 2024

Ethical considerations on the use of big data and artificial intelligence in kidney research from the ERA ethics committee (2024)

How high-quality observational studies can complement randomized trial evidence by benchmarking results against trial findings and then extending them.

Fu et al. BMJ 2021

KDIGO guideline on CKD Evaluation and Management (2023)

Optimal timing of dialysis (practice point 5.4.3).

Fu et al. BMJ 2021

Use eGFRcr-cys when eGFRcr is less accurate (practice point 1.2.2.1).

Fu et al. J Am Soc Nephrol 2023

Continue ACE/ARB in people with advanced CKD (practice point 3.5.7).

Fu et al. J Am Soc Nephrol 2021

Discontinue ACEi/ARB/MRA after AKI or hyperkalemia (practice point 4.3.3).

Janse, Fu et al. CKJ 2022; Xu, Fu et al. Am Heart J 2022; Trevisan, Fu et al. Eur J Heart Fail 2021; Bidulka, Fu et al. BMC Med 2020

Overview of evaluation, diagnosis and staging of CKD (chapter 1 of guideline).

CKD Prognosis Consortium. JAMA 2023

European Renal Association position statement (2023)

Whether CKD-EPI 2021 equation should be implemented in Europe. The statement was adopted by the Dutch Federation of Nephrology.

Fu et al. NDT 2023

European Federation of Clinical Chemistry and Laboratory Medicine position statement (2023)

Whether CKD-EPI 2021 equation should be implemented in Europe. The statement was adopted by the Dutch Federation of Nephrology.

Fu et al. NDT 2023

KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD (2022)

Stopping vs. continuing ACEi/ARB

Fu et al. J Am Soc Nephrol 2021

NICE real-world evidence guideline (2022)

How observational real-world evidence studies should be performed (our paper was used as positive use-case)

Fu et al. BMJ 2021

The team

I am proud to be supervising a talented team of people. They work on a range of projects that are related to my research lines. We work with many collaborators that I am fortunate to have in my international network.

Sherry Zhang

PhD student, LUMC

Malou Magnani

Research intern, LUMC

Antoine Créon

PhD student, Karolinska Insititute

Roosa Lankinen

Postdoc, Karolinska Institute

Alumni

Roemer Janse, MSc Medicine, LUMC (2021-2022)
Carole Marxer, Postdoc, Karolinska Institute (2023-2024)

Talks

Over the years, I have shared my research globally in numerous talks. For example, I have been invited as speaker at Harvard, Karolinska Institute, Aarhus University, Johns Hopkins, UCL and the Japanese Society of Nephrology. My talks focus either on relevant clinical results, or educating peers about causal inference - specifically target trial emulation. For a list of talks and links to online resources, click the button below.

Biography

Soon after the start of my medicine studies, epidemiologic research piqued my interest. I feel fortunate that I can currently combine both passions to become MD and continue informing clinical guidelines with my research. See my biography for more on my background and research.

Research lines

Cardiometabolic and renal pharmacoepidemiology

Diagnosis and epidemiology of chronic kidney disease

Personalized medicine

Our impact on clinical guidelines

Research Highlights